Takeda Pharmaceuticals Articles
Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study
20 May 2013
Japan briefs: Takeda files for Azilva comb; Sandoz seeks filgrastim biosimilar approval
29 April 2013
Takeda considering options over US Actos court ruling
29 April 2013
MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world
8 April 2013
Takeda taps Resolve for lupus disease candidate
1 March 2013
Takeda and Affymax recall all lots of anemia drug Omontys
25 February 2013
Takeda called on to take corrective action over Alinamin-F5 marketing and manufacturing
15 February 2013
Torrey Pines Institute collaborates with Takeda unit
28 January 2013
FDA approves three Takeda diabetes drugs; expands use of Novartis' Gleevec and Pfizer's Prevnar 13
28 January 2013
Japan launches for Lotriga and Argamate
11 January 2013
Infinity amends PI3K-delta, gamma accord with Millennium
28 December 2012
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Takeda sells non-Colcrys URL Pharma generic business to Sun Pharma; Eisai divests Gliadel Wafer in USA
17 December 2012
Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders
11 December 2012
FDA grants Seattle Genetics' Adcetris orphan rating in MF
27 November 2012
Takeda debuts Hodgkin lymphoma drug Adcetris in UK
19 November 2012
European Commission grants conditional approval for Adcetris
1 November 2012
More highlights from ESMO Congress
2 October 2012
Pharmaceutical majors unite in Japan to combat H. pylori
18 September 2012
Playing ball with Russia in the pharma sector
16 September 2012
Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021
16 September 2012
Takeda completes 75 million-euro Russian pharmaceutical production plant
11 September 2012
Takeda's Revestive gets EU clearance for short bowel syndrome
5 September 2012
Watson sues US FDA regarding generic Actos approval delay
16 August 2012
Japan's drug majors post mixed financial results
31 July 2012
Sucampo fails in Amitiza arbitration with Takeda
9 July 2012
EMA backs approval of Revestive, Zinforo and Seebri Breezhaler, but not Elelyso; Hexaxim opinion
25 June 2012
Lundbeck and Takeda to file for Lu AA21004 approval in USA and Europe on strong Ph III results
15 May 2012
Par Pharma acquires Handa's ANDA for generic Dexilant
23 April 2012
Affymax and Takeda get special Medicare code for Omontys
16 April 2012
Takeda to acquire URL Pharma for $800 million
12 April 2012
Nycomed debuts Omnaris nasal spray in the UAE
14 March 2012
Takeda's GPR40 agonist for diabetes promising in Ph II trial
28 February 2012
Takeda sets up development center in China
13 February 2012
Another FDA hurdle for Orexigen obesity drug candidate
7 February 2012
Sucampo’s OBD drug meets Ph III endpoint
2 February 2012
Costs take toll on earnings from Japan’s Takeda
1 February 2012
Takeda cuts 2,800 jobs as it assimilates Nycomed
19 January 2012
EC backs continued use of pioglitazone drugs for diabetes
10 January 2012
Mylan confirms Actoplus patent challenge
9 January 2012
Takeda ends Daxas co-promotion with MSD; Actos law suits
3 January 2012
Takeda’s Steovess accepted for national approvals in EU
23 December 2011
Takeda gets US regulatory backing for Edarbyclor
21 December 2011
5.6% annual growth forecast for multiple myeloma drug market to 2020
21 December 2011
Takeda boosts oncology pipeline with acquisition
21 December 2011
Takeda to drop peginesatide commercialization in Japan
19 December 2011
Takeda’s Edarbi Oked in EU
12 December 2011
FDA committee backs Affymax CKD drug
9 December 2011
Takeda to establish dedicated vaccine business division
6 December 2011
US FDA sets PUDFA date for Takeda diabetes drug alogliptin and fixed-dose alogliptin/pioglitazone
2 November 2011
Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report
1 November 2011
Sanofi to top Pfizer as number one for global pharma sales
1 November 2011
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
